TY  - JOUR
AU  - Lopez-Vivanco, G
AU  - Salvador, J
AU  - Diez, R
AU  - López, D
AU  - De Salas-Cansado, M
AU  - Navarro, B
AU  - De la Haba-Rodriguez, J
PY  - 2017
DO  - 10.1007/s12094-017-1684-4
UR  - http://hdl.handle.net/10668/11267
T2  - Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
AB  - To describe healthcare professional (HCP) and patient time and related costs associated with trastuzumab intravenous infusion (IV) and trastuzumab subcutaneous (SC) formulations in patients with HER2-positive early breast cancer. This prospective,...
LA  - en
PB  - Springer Milano
KW  - Spain
KW  - Time and motion
KW  - Trastuzumab
KW  - Administration, Intravenous
KW  - Antineoplastic Agents
KW  - Breast Neoplasms
KW  - Costs and Cost Analysis
KW  - Female
KW  - Follow-Up Studies
KW  - Humans
KW  - Injections, Subcutaneous
KW  - Middle Aged
KW  - Prognosis
KW  - Prospective Studies
KW  - Receptor, ErbB-2
KW  - Spain
KW  - Trastuzumab
TI  - Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain.
TY  - research article
VL  - 19
ER  -